Company: MIRA
Filing Date: 2025-05-14
Form Type: 10-Q
Source: 0001641172-25-010301
Chunk: 12

Company: MIRA PHARMACEUTICALS, INC.
Filing Date: 2025-05-14
Form: 10-Q
Item: Item 8
Chunk 12
---
    2025  
    2024 
  
    Revenues 
    $—  
    $— 
  
    Less segment expenses: 

    Research and development 
     314,404  
     762,276 
  
    General and administrative 
     1,490,796  
     1,005,911 
  
    Loss from operations 
    $1,805,200  
     1,768,187 
  
    Plus: 

    Interest income 
     21,421  
     50,416 
  
    Segment net loss 
    $(1,783,779) 
    $(1,717,771)

Note
7. Subsequent Events

ATM
Offering

On
April 16, 2025, the Company filed a prospectus supplement to amend the shelf registration statement to update the maximum amount eligible
to be sold under the ATM Agreement to $7 million.

From
April 1, 2025 through May 14, 2025, under the ATM Agreement, the Company sold and issued 105,969 shares of Common Stock at
an average price per share of $0.90, and received net proceeds of approximately $0.1 million, after deducting commissions and other
fees of $0.003 million.

 12 

CAUTIONARY
NOTE REGARDING FORWARD-LOOKING STATEMENTS

This
Report contains “forward-looking statements” (as defined in Section 27A of the Securities Act of 1933, as amended, and Section
21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act) that reflect our current expectations and views of future
events. In some cases, you can identify forward-looking statements by terms such as “may,” “will,” “should,”
“expect,” “plan,” “anticipate,” “could,” “intend,” “target,”
“project,” “contemplate,” “believe,” “estimate,” “predict,” “potential”,
or “continue” or the negative of these terms or other similar expressions. In particular, statements about our clinical trials and expectations regarding such trials, the markets in which we operate, including growth of such markets, and our
expectations, beliefs, plans, strategies, objectives, prospects, assumptions, or future events or performance contained in this Report
generally under the heading “Management’s Discussion and Analysis of